Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic of Milnacipran Hydrochloride Tablets
Elmwood Park, New Jersey, March 19, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Milnacipran Hydrochloride Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg. This product is the authorized generic to Savella® Tablets.According to IQVIA™ sales data for the 12-month period ending January 2026, the Savella® Tablets market achieved annual sales of approximately $102.9 million*.
Marc Kikuchi, President & Business Head, North America, stated, "We are excited to announce the launch of Milnacipran Hydrochloride Tablets, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring quality and affordable alternatives for patients."
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company. The company operates 11 manufacturing facilities and six research and development centers, and has a commercial presence in over 80 countries.
*IQVIA™ National Sales Perspectives: Retail & Non-Retail, January 2026
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.